-
Survey Highlights European MS Therapy Switches
Novartis’ Gilenya, Sanofi Genzyme’s Aubagio, and Biogen’s Tysabri and Tecfidera dominate recent MS therapy switches in Europe, a Spherix survey found. Read the full story here.
What do you think of this story? Does this surprise you?
Sorry, there were no replies found.
Log in to reply.